Literature DB >> 9694973

Pharmacology of [3H]prostaglandin E1/[3H]prostaglandin E2 and [3H]prostaglandin F2alpha binding to EP3 and FP prostaglandin receptor binding sites in bovine corpus luteum: characterization and correlation with functional data.

N A Sharif1, S X Xu, G W Williams, J Y Crider, B W Griffin, T L Davis.   

Abstract

Specific binding of [3H]prostaglandin (PG) E1, [3H]PGE2 and [3H]PGF2alpha to washed total particulate homogenates of bovine corpus luteum comprised 60 to 82% of total binding. Scatchard analysis of competition data revealed the presence of an apparent single population of binding sites for [3H]PGE1 and [3H]PGE2 with dissociation constants (Kds) of 2.76 to 3.39 nM and apparent receptor density (Bmax) of 1.5 to 1.56 pmol/g wet weight (n = 3-4). However, [3H]PGF2alpha appeared to interact with two classes/states of binding sites (Kd1 = 6.51 +/- 0.65 nM, Bmax1 = 2.33 +/- 0.26 pmol/g wet weight; Kd2 = 986 +/- 269 nM; Bmax2 = 44.8 +/- 11.3 pmol/g wet weight, n = 11). Specific [3H]PGE1 and [3H]PGE2 binding was most potently (nanomolar affinity) inhibited by PGs with high selectivity for the EP3 receptor subtype (e.g., GR63799, sulprostone, enprostil) but was weakly (Kis > 1 microM) influenced by EP1-selective (SC-19220), FP-selective (fluprostenol, PHXA85), DP-selective (BWA868C; ZK118182), IP-selective (iloprost) and TP-selective (U46619) PGs. Specific [3H]PGF2alpha binding was potently displaced by FP-selective agents such as fluprostenol, PHXA85 and cloprostenol with nanomolar affinities (n = 3-25), but weakly (Kis > 1 microM) by other PGs showing high selectivity for other PG receptor subtypes mentioned above. The relative specificities and potencies of EP3- and FP-selective PGs tested in the binding assays were confirmed using various functional assays. These studies have provided strong pharmacological evidence for the similarity of [3H]PGE1 and [3H]PGE2 binding to EP3 receptors and for [3H]PGF2alpha binding to FP receptors in washed bovine corpus luteum homogenates.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694973

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Prostacyclin receptor deletion aggravates hippocampal neuronal loss after bilateral common carotid artery occlusion in mouse.

Authors:  G Wei; K K Kibler; R C Koehler; T Maruyama; S Narumiya; S Doré
Journal:  Neuroscience       Date:  2008-08-20       Impact factor: 3.590

2.  Effect of fish meal supplementation on spatial distribution of lipid microdomains and on the lateral mobility of membrane-bound prostaglandin F receptors in bovine corpora lutea.

Authors:  M R Plewes; P D Burns; P E Graham; J E Bruemmer; T E Engle; B G Barisas
Journal:  Domest Anim Endocrinol       Date:  2017-02-14       Impact factor: 2.290

Review 3.  Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma.

Authors:  Peter G Klimko; Najam A Sharif
Journal:  Br J Pharmacol       Date:  2018-05-17       Impact factor: 8.739

4.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

5.  Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins.

Authors:  L Walch; V de Montpreville; C Brink; X Norel
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

6.  Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: pharmacological characterization using agonists and antagonists.

Authors:  J Y Crider; B W Griffin; N A Sharif
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

7.  Effect of fish oil on lateral mobility of prostaglandin F (FP) receptors and spatial distribution of lipid microdomains in bovine luteal cell plasma membrane in vitro.

Authors:  M R Plewes; P D Burns; P E Graham; R M Hyslop; B G Barisas
Journal:  Domest Anim Endocrinol       Date:  2016-08-12       Impact factor: 2.290

8.  Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor.

Authors:  T L Davis; N A Sharif
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 9.  Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility.

Authors:  Najam A Sharif; Peter G Klimko
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

10.  Embryo-luteal cells co-culture: an in vitro model to evaluate steroidogenic and prostanoid bovine early embryo-maternal interactions.

Authors:  Ana Torres; Mariana Batista; Patrícia Diniz; Luisa Mateus; Luís Lopes-da-Costa
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-01-29       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.